Beta
165163

Metalloporphyrins: Radioprotector and Radiosensitizer

Article

Last updated: 22 Jan 2023

Subjects

-

Tags

Section D: Clinical Pharmacy & Pharmacology

Abstract

Cancer has become the leading cause of human death in the world, due to its uncontrolled and rapid proliferation properties. Radio and chemotherapy are used in the treatment of almost all types of cancer. They mostly act by increasing the production of reactive oxygen specious (ROS) and free radicals. ROS levels are believed to be higher in cancer cells compared to their normal counterparts this is suggested to be related to cancer cell growth, angiogenesis, and metastasis. Although the cure rate for many types of cancer would be increased by radiation dose escalation, balancing the potential for cure against the risk for normal tissue injury is a complex endeavor. Because normal tissue toxicity during radiotherapy and pathological conditions that include overproduction of unstable oxygen species, efforts are ongoing to develop new radioprotective drugs. Antioxidants is an example of co treatment which has potential to protect normal tissues against radiation-induced damage with increasing IR-induced damage for cancer. Since the discovery of superoxide dimutases (SODs), a family of metalloproteins, it has become clear that these enzymes provide an essential defense against the superoxide radical. Application of native SOD has been limited due to short half-lives, lack of cellular uptake and hypersensitivity. Metal-containing SOD mimetics have now emerged as being especially promising, they have been used for treatment of different kinds of diseases, as cancer. It is believed to protect cells from radiation damage by removing free radicals produced by irradiation. The objective of this review is to summarize the most current metalloporphyrin as an example of SODm in treatment of cancer and in combination with other radio and chemotherapy.

DOI

10.21608/aprh.2021.55777.1121

Keywords

SOD, metalloporphyrin, Cancer, ROS

Authors

First Name

Yasmin

Last Name

Alzarie

MiddleName

-

Affiliation

Department of Internal Medicine, Davis Heart & Lung Research Institute, College of Medicine, The Ohio State University, Columbus, Ohio 43210, USA. , National Organization of Drug Control and Research, Cairo, Egypt.

Email

dr.yasmina2011@gmail.com

City

-

Orcid

-

First Name

Osama

Last Name

Badary

MiddleName

-

Affiliation

Department of Pharmacology, Faculty of Pharmacy, British University in Egypt.

Email

obadary@yahoo.com

City

-

Orcid

-

First Name

Shahira

Last Name

Nofal

MiddleName

-

Affiliation

Department of Pharmacology and Toxicology, College of Pharmacy, Helwan University, Cairo, Egypt.

Email

shahira.nofal@pharm.helwan.edu.eg

City

-

Orcid

-

Volume

5

Article Issue

2

Related Issue

24440

Issue Date

2021-04-01

Receive Date

2020-12-29

Publish Date

2021-04-01

Page Start

276

Page End

284

Print ISSN

2357-0547

Online ISSN

2357-0539

Link

https://aprh.journals.ekb.eg/article_165163.html

Detail API

https://aprh.journals.ekb.eg/service?article_code=165163

Order

3

Type

Review Article

Type Code

358

Publication Type

Journal

Publication Title

Journal of Advanced Pharmacy Research

Publication Link

https://aprh.journals.ekb.eg/

MainTitle

-

Details

Type

Article

Created At

22 Jan 2023